Clinical Trial: Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes

U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07383155) titled 'Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes' on Jan. 24.

Brief Summary: Background. Randomized data on the optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) are lacking.

Methods. BRIGHT-HBR is an investigator-sponsored, open-label, randomized controlled trial comparing bivalirudin vs. unfractionated heparin (UFH) monotherapy in HBR patients with ACS undergoing PCI. A total of 5270 HBR patients with a non-ST-elevation acute coronary syndrome (NSTE-ACS) or recent stabilized ST-s...